Stockscreener 앱 받기
0.4601
3.39%
0.0151
전일 마감가:
$0.445
열려 있는:
$0.45
하루 거래량:
235.62K
Relative Volume:
0.50
시가총액:
$28.53M
수익:
-
순이익/손실:
$-151.16M
주가수익비율:
-0.1549
EPS:
-2.97
순현금흐름:
$-130.08M
1주 성능:
+1.66%
1개월 성능:
-17.05%
6개월 성능:
-74.58%
1년 성능:
-91.78%
1일 변동 폭
$0.4452
$0.468
1주일 범위
$0.404
$0.468
52주 변동 폭
$0.404
$8.78
AIx 온콜로지 Stock (ALXO) Company Profile
명칭
Alx Oncology Holdings Inc
전화
650-466-7125
주소
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
ALXO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.4601 | 28.53M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
AIx 온콜로지 Stock (ALXO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-06 | 개시 | UBS | Buy |
| 2021-02-10 | 개시 | H.C. Wainwright | Buy |
| 2020-08-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 개시 | Credit Suisse | Outperform |
| 2020-08-11 | 개시 | Jefferies | Buy |
| 2020-08-11 | 개시 | Piper Sandler | Overweight |
모두보기
AIx 온콜로지 주식(ALXO)의 최신 뉴스
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
ALX Oncology Confirms Directors at Annual Meeting - TipRanks
ALX Oncology reports annual meeting results By Investing.com - Investing.com Nigeria
ALX Oncology reports annual meeting results - Investing.com
Cantor Fitzgerald Weighs in on ALX Oncology FY2026 Earnings - Defense World
ALX Oncology (NASDAQ:ALXO) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Nuveen Asset Management LLC Has $275,000 Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Acquired by Two Sigma Investments LP - Defense World
Bank of America Corp DE Grows Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Acquired by Deutsche Bank AG - Defense World
Northern Trust Corp Acquires 23,324 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - GlobeNewswire
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference | ALXO Stock News - GuruFocus
ALX Oncology Management to Showcase Novel Cancer Treatment Advances at Major Jefferies Healthcare Conference - Stock Titan
D. E. Shaw & Co. Inc. Decreases Stock Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
H.C. Wainwright maintains ALX Oncology stock Buy rating By Investing.com - Investing.com India
H.C. Wainwright maintains ALX Oncology stock Buy rating - Investing.com
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO) - The Globe and Mail
UBS Group Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ALXO: UBS Maintains 'Buy' Rating, Lowers Price Target | ALXO Sto - GuruFocus
ALXO: UBS Maintains 'Buy' Rating, Lowers Price Target | ALXO Stock News - GuruFocus
UBS Adjusts Price Target on ALX Oncology Holdings to $1 From $1.20, Maintains Buy Rating - marketscreener.com
ALX Oncology presents preclinical data, plans for ALX-2004 - BioWorld MedTech
UBS Adjusts Price Target for ALX Oncology (ALXO) to $1 | ALXO St - GuruFocus
UBS Adjusts Price Target for ALX Oncology (ALXO) to $1 | ALXO Stock News - GuruFocus
Transcript : ALX Oncology Holdings Inc.Special Call - marketscreener.com
ALX Oncology : Investor Presentation ALX2004 Webcast May 20 2025 Final (2a4ce1) - marketscreener.com
ALX Oncology Holdings Inc. Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - marketscreener.com
ALXO Unveils Advanced Antibody-Drug Conjugate ALX2004 for Tumor Treatment | ALXO Stock News - GuruFocus
ALX Oncology Highlights Differentiated Design, Preclinical - GlobeNewswire
First-in-Class Cancer Drug: ALX Oncology's Novel EGFR-ADC Gets FDA Green Light for Clinical Trials - Stock Titan
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Cubist Systematic Strategies LLC - Defense World
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EG - GuruFocus
ALX Oncology to Host R&D Webcast Event Highlighting its - GlobeNewswire
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - Stock Titan
HC Wainwright Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
ALXO Stock: HC Wainwright & Co. Lowers Price Target | ALXO Stock News - GuruFocus
ALX Oncology Reports Q1 2025 Financial Results - TipRanks
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
ALXO Advances Cancer Therapy Focus and Pipeline Development | AL - GuruFocus
ALXO Advances Cancer Therapy Focus and Pipeline Development | ALXO Stock News - GuruFocus
ALX ONCOLOGY Earnings Results: $ALXO Reports Quarterly Earnings - Nasdaq
Financial Health Check: Examining Alx Oncology Holdings Inc (ALXO)’s Key Ratios - DWinneX
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ALX Oncology to Report First Quarter 2025 Financial Results on M - GuruFocus
ALX Oncology Holdings Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Will ALXO Make A Comeback In July? - RTTNews
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | ALXO Stock News - GuruFocus
AIx 온콜로지 (ALXO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
AIx 온콜로지 주식 (ALXO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 19 '25 |
Sale |
1.15 |
550 |
633 |
87,352 |
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
| Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
| Pinto Shelly | Interim CFO |
Dec 30 '24 |
Sale |
1.58 |
1,426 |
2,253 |
90,123 |
| Pons Jaume | PRESIDENT & CSO |
Dec 30 '24 |
Sale |
1.58 |
10,796 |
17,060 |
580,714 |
| Hemrajani Rekha | Director |
Dec 02 '24 |
Buy |
1.55 |
30,000 |
46,404 |
33,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 14 '24 |
Sale |
2.58 |
564 |
1,455 |
91,549 |
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Aug 14 '24 |
Sale |
2.58 |
1,365 |
3,522 |
325,711 |
| Pons Jaume | PRESIDENT & CSO |
Aug 14 '24 |
Sale |
2.58 |
1,937 |
4,997 |
591,510 |
0.68%
0.50%
자본화:
|
볼륨(24시간):